Efficacy and safety analysis of Dupilumab for atopic dermatitis of all ages in Chinese population: Real‐world data from a single center.

This article presents a real-world study conducted at Ruijin Hospital in Shanghai, China, to evaluate the efficacy and safety of Dupilumab, a monoclonal antibody used to treat atopic dermatitis (AD) in Chinese patients. The study included 689 patients of all ages who were treated with Dupilumab. The results showed that Dupilumab was effective in reducing symptoms of AD, with the greatest improvement observed in the first 8 weeks of treatment. Factors such as age, gender, and baseline eosinophil counts were found to influence the therapeutic effect. The incidence of adverse events was generally low, with most events being mild and tolerable. Some rare infections, phenotype switching, and tumor events were also observed. The study provides valuable insights into the efficacy and safety of Dupilumab in the Chinese population. [Extracted from the article]